Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins.

Bays, Harold E; Baum, Seth J; Brinton, Eliot A; Plutzky, Jorge; Hanselman, Jeffrey C; Teng, Rujun; Ballantyne, Christie M

Bays, Harold E; Baum, Seth J; Brinton, Eliot A; Plutzky, Jorge; Hanselman, Jeffrey C; Teng, Rujun; Ballantyne, Christie M.

Afiliação

Bays HE; Louisville Metabolic and Atherosclerosis Research Center, Inc., Louisville, KY, USA.
Baum SJ; Excel Medical Clinical Trials, Inc., Boca Raton, FL, USA.
Brinton EA; Utah Lipid Center, Salt Lake City, UT, USA.
Plutzky J; Brigham and Women's Hospital, Boston, MA, USA.
Hanselman JC; Esperion Therapeutics, Inc., Ann Arbor, MI, USA.
Teng R; Esperion Therapeutics, Inc., Ann Arbor, MI, USA.
Ballantyne CM; Baylor College of Medicine, Houston, TX, USA.

Am J Prev Cardiol ; 8: 100278, 2021 Dec.

Article em En | MEDLINE | ID: mdl-34746903

Palavras-chave

Bempedoic acid; Diabetes mellitus type 2; Ezetimibe; Hypercholesterolemia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Am J Prev Cardiol Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google